Research Matters

Click here to view previous editions of Research Matters and Research News and Updates.




Latest News

Research Newsletter
January 20, 2015  

Case-Coulter Translational Research Partnership (CCTRP)

This is the fourth year of the second phase of the Case-Coulter Translational Research Partnership (CCTRP) to support collaborative translational research projects that address unmet or poorly met clinical needs. The CCTRP seeks to reduce the market risk of promising new clinical products arising from the research programs of BME and other Case faculty. Successful projects will thus often focus on the development of prototype products, building relationships with companies, performing clinical feasibility studies, obtaining regulatory approval, and other activities that companies or business experts indicate are the essential last steps before a license can be negotiated or a startup launched. An overarching goal of the program is to foster research and development work likely leading to commercially relevant translational technologies within a three- to five-year horizon. Because the goals of all Coulter projects are to reduce market risk, all proposals are expected to reflect genuine business input, and all projects must include a “business advisor” as an important member of the decision making team.

Awards up to $200,000 will be considered if well justified.

Letter of Intent Deadline: February 13, 2015

For more information visit the BME website.

 
FBI Talk on International Travel

Monday, February 9, 2015
12 pm - 1 pm
Toepfer Room, Adelbert Hall


Are you a researcher who travels abroad to attend scientific or academic conferences? To meet with potential sponsors, donors, or collaborators? To teach at a foreign university or travel with students on an international trip?

Join FBI representatives who will present cutting-edge information on travel concerns for university faculty and employees traveling abroad.

There is no pre-registration. Seating is limited and is first come, first seated.

For more information, contact Lisa Palazzo, Director of Export Control and Privacy Management, at 216.368.5791 or lisa.palazzo@case.edu, or Boyd Kumher, University Chief Compliance, Export Control and Privacy Officer, at 216.368.0833 or boyd.kumher@case.edu.

 
NIH Center for Accelerated Innovation at Cleveland Clinic (NCAI-CC)

The NIH Center for Accelerated Innovation at Cleveland Clinic (NCAI-CC) Announces the Request for Applications (RFA) for the third funding cycle.

Funding is available for promising emerging technologies directed towards diagnosis, treatment or management of cardiovascular, pulmonary, blood or sleep-related disorders. NCAI-CC is seeking projects such as therapeutics (e.g. drugs, biologics), preventatives, diagnostics, devices, tools, etc., in order to facilitate their translation to commercialized products that improve patient care and enhance health. The NCAI-CC will provide funding and project assistance to advance the development of high priority early-stage technologies within the mission areas of the NHLBI (cardiovascular, lung, blood and sleep disorders). Expert assistance will be provided in areas required for early technology development, including commercial opportunity assessment, intellectual property, clinical and regulatory, reimbursement, business, legal and project management.

Eligibility: Investigators from the Cleveland Clinic, Case Western Reserve University, The Ohio State University,Cincinnati Children’s Hospital, and University of Cincinnati

Letter of Intent Deadline: February 10, 2015

For more information visit the NCAI-CC website.

 

Foundation Fighting Blindness and Harrington Discovery Institute

Foundation Fighting Blindness and Harrington Discovery Institute have partnered to form, the The National Center for Excellence in Fighting Blindness, a Gund-Harrington initiative. This initiative is focused on accelerating the translation of research findings in inherited retinal degenerative diseases (IRD) with the ultimate goal of developing new therapies to improve and/or restore vision.

• This Initiative seeks to award Gund-Harrington Scholar Awards that recognize innovators throughout the USA whose research has the potential to advance standards of care.
• There will be an average of three awards per year, which will be restricted to researchers working at institutions within the USA. Applications from outside the USA are not accepted.
• The Gund-Harrington Scholar Award provides funding for translational drug development and cell therapy along with non-financial project support to help bridge the gap between laboratory-based research and the clinic.
• Funding up to a total of $900,000 over three years and non-financial support will be provided by the The National Center for Excellence in Fighting Blindness. The non-financial support, provided by a team of pharmaceutical experts, will include project management and experienced industry advice in all aspects of drug development, encompassing chemistry, formulation, toxicology, regulatory, intellectual property and business development.
• Awards will be made to physician-scientists, or scientists with a research team that includes significant involvement of a physician with clinical expertise in the IRD.
• Selected projects must demonstrate a reasonable expectation that they can develop a lead product with strong potential for clinical and commercial application by the end of the three year funding period.
Multi-disciplinary investigators outside the field of retinal disease are particularly encouraged to apply.

Applicants interested in the Gund-Harrington Scholar Awards must apply through Foundation Fighting Blindness.

For more information about Foundation Fighting Blindness visit the Fighting Blindness website.

 
New Facilities and Administrative (F&A) Rate for Use in Proposals

Negotiations with the Department of Health and Human Services (DHHS) regarding the University’s F&A rates have concluded. DHHS has approved a (3) three year F&A rate of 58.5% for CWRU, which is a 1.5 percentage point change from our previous rate of 57%. This rate will be effective through June 2016.

The new F&A rate should be used when preparing proposal budgets for awards with an anticipated start date of July 1, 2013 or after.

Read the full notice of this change at: https://ora.ra.cwru.edu/research/docs/2012.10.08_Facilities_and_Administrative_rate.pdf.

 

If you have news or information that you wish to have included in this update, please send it via e-mail to Tracy Wilson-Holden at tracy.wilson-holden@case.edu no later than 5 pm on the Monday of the week that the update is to be distributed. If you know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe to Case Research News, email your request to Tora Williams at tora.williams@case.edu.

Please note: At the time of this transmission, all links functioned. However, Case Research News cannot guarantee that the information will not move or be deleted.